Moderna reported positive Phase 3 results for its mRNA seasonal influenza vaccine candidate, mRNA-1010, showing stronger protection than the standard flu shot in a large adult study population. Regulatory submissions for mRNA-1010 are in progress in the US, Europe, Canada, and Australia, with the US FDA reviewing the data and an approval decision expected later this year. Separately, Moderna advanced its mRNA-based hantavirus vaccine collaboration with Korea University's Vaccine Innovation...

Investing.com -- Moderna (NASDAQ:MRNA) shares climbed 10% on Thursday as concerns mounted over a hantavirus outbreak connected to a cruise ship.

Moderna (NASDAQ:MRNA) shareholders approved all four management proposals at the company’s 2026 Annual Meeting of Shareholders, including the re-election of two directors, advisory votes related to executive compensation, and the ratification of Ernst & Young as the company’s independent auditor

Moderna has notably outperformed the broader market over the past year, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Operational revenue from Pfizer’s Covid vaccine Comirnaty and Paxlovid pill to treat the illness declined 59% and 63%, respectively.

Raising capital while still building the data needed to validate an idea is often one of the biggest hurdles for start-ups.